Skip to main content
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. — Investor Relations & Filings

Ticker · SLS ISIN · US81642T2096 LEI · 549300VZIH50VYURLQ98 US Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2012-11-13 Regulatory Filings
Country US United States of America
Listing US SLS

About SELLAS Life Sciences Group, Inc.

https://www.sellaslifesciences.com/

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's core activity involves advancing its pipeline of cancer immunotherapies, which are designed to utilize the patient's immune system to combat various malignancies. Its development programs aim to address significant unmet medical needs in oncology by creating new treatment options for cancer patients.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the company issued a press release announcing financial results for the quarter ended September 30, 2012, and that the press release is attached as Exhibit 99.1. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 2957 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, if a document is short and states that a report or press release is attached or published, it should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR). Therefore, this document is best classified as a Regulatory Filing (RNS).
2012-11-13 English
FORM 10-Q
Interim / Quarterly Report Q3 2012
2012-11-13 English
PRIMARY DOCUMENT
Director's Dealing
2012-11-06 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Galena Biopharma, Inc. It registers shares of common stock under the company's Amended and Restated 2007 Incentive Plan. The document includes details about the securities to be registered, calculation of registration fees, exhibits, and signatures. Form S-8 is a registration statement used for securities issued under employee benefit plans, which is a type of capital raising or share issuance activity. It is not an annual report, earnings release, or any other financial report. Therefore, the document fits best under the category related to capital or financing updates, specifically share issuance or capital changes.
2012-08-14 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing financial results for the quarter ended June 30, 2012, and that the press release is attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 2930 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces or furnishes financial results without containing the full report itself should be classified as an Earnings Release (ER).
2012-08-14 English
10-Q
Interim / Quarterly Report Q2 2012
2012-08-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.